Elagolix and Rifadin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

RifAMPin may significantly increase the blood levels of elagolix. This can increase the risk and/or severity of side effects such as bone loss, depression, mood changes, suicidal thoughts, and liver problems. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. If both medications are necessary, a dosage reduction of elagolix may be required, and it is generally recommended that the duration of concurrent use be limited to 6 months at most. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with rifampin may significantly increase the plasma concentrations of elagolix. The proposed mechanism is inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of elagolix by rifampin. In 12 study subjects, coadministration of single doses of 150 mg elagolix and 600 mg rifampin increased elagolix peak plasma concentration (Cmax) and systemic exposure (AUC) by 337% and 458%, respectively, compared to elagolix administered alone. When the same dose of elagolix was administered following multiple daily dosing of 600 mg rifampin, elagolix Cmax and AUC increased by 100% and 65%, respectively. The reduced effect of rifampin on elagolix plasma concentrations during chronic administration relative to single-dose administration likely stems from rifampin induction of CYP450 3A4, of which elagolix is also a substrate. Increased exposure to elagolix may increase the risk of serious adverse effects such as bone loss, suicidal ideation and behavior, exacerbation of mood disorders, and hepatic transaminase elevations.

MANAGEMENT: Concomitant use of elagolix 200 mg twice daily with rifampin is not recommended. Concomitant use of elagolix 150 mg once daily with rifampin should be limited to 6 months.

Elagolix

Generic Name: elagolix

Brand name: Orilissa

Synonyms: n.a.

What is Elagolix?

Rifadin

Generic Name: rifampin

Brand name: Rifadin, Rifadin IV, Rimactane

Synonyms: n.a.

What is Rifadin?